Developing first in class solutions for unmet health and personal care needs

NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference

Nov 1, 2021

by Paul McIntosh | Oct 29, 2021 | 2021, Press Releases | 0 comments Highlights new insights into cysteamine’s mechanism of action against Pseudomonas aeruginosa and Burkholderia cenocepacia, further supporting cysteamine’s potential as an antimicrobial intervention in...

« Older Entries

Next Entries »

NovaBiotics Pharma Division Highlighted in Healthcare UK report

The company and its Research & Development activities to tackle antimicrobial resistance, infectious and respiratory disease was highlighted in a recent report by Healthcare UK, a joint initiative of the Department of Health and Social Care, NHS England and the...

NovaBiotics announces move to ONE BioHub

Innovative biotechnology group company NovaBiotics has confirmed that NovaBiotics and NovaBiotics Consumer Health will move into ONE BioHub in Aberdeen. Full details are available here ONE News

NovaBiotics Consumer Health Signs Global Sales and Distribution Agreement for its Breakthrough Nail Health Solution, Tinexyl®.

NovaBiotics Consumer Health Limited (“NCH”), a division of NovaBiotics Limited (“NovaBiotics” or “the Company”), today announced that it has entered into a distribution agreement with Brand Creations Limited (“BCL, for the rights to commercialise and distribute...

TinexylPRO Launched at Key Industry Events

The Institute of Podiatrists (IOP) successfully launched our next-generation personal care nail health system on their stand at the Primary Care Show, May 15th-16th. The IOP will also showcase this highly innovative product at FootHealth 2024, June 3rd-4th. These...

Appointment of Dr Trevor Phillips to the Board of NovaBiotics

ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director. Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech...

Publication of NovaBiotics’ peer reviewed research on cysteamine’s antiviral and anti-inflammatory mechanisms

Publication of NovaBiotics’ research on the host-mediated anti-viral (including against coronaviruses and influenza) and anti-inflammatory mechanism of action of cysteamine, the active component of its advanced clinical stage NM001 and NM002 product candidates for...

Additional International Organization for Standardisation (ISO) accreditations for NovaBiotics

NovaBiotics adds ISO 14001: 2015 and ISO 45001: 2018 accreditations to its integrated quality management system. ISO 14001: 2015 Environmental Management Systems and ISO 45001:2018 Occupational Health & Safety Systems accreditation have now been awarded to...

NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases

New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...

NovaBiotics to Present at the H.C. Wainwright BioConnect Conference

Aberdeen, January 4, 2022 - NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that Dr Deborah O’Neil OBE, FRSE, Chief Executive Officer of NovaBiotics,...

NovaBiotics Announces First Patient Enrolment into the Cysteamine Domain of REMAP-CAP

NovaBiotics’ NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias Aberdeen, December 8, 2021. NovaBiotics Ltd, a privately held clinical stage company developing...